Alternative detection of SARS-CoV-2 RNA by a new assay based on mass spectrometry release_qdxikk35yngqvjg57us7ka7ad4

by Evelyn Stelzl, Harald H. Kessler, Hans G. Mustafa, Maria E. Mustafa, Brigitte I. Santner, Josef Seier, Marco La Torre, Alexander C. Haushofer

Published in Clinical Chemistry and Laboratory Medicine by Walter de Gruyter GmbH.

2021  

Abstract

<jats:title>Abstract</jats:title> <jats:sec id="j_cclm-2021-0483_abs_001_w2aab3b7ab1b6b1aab1c11b1Aa"> <jats:title>Objectives</jats:title> Accurate detection of SARS-CoV-2 RNA is essential to stopping the spread of SARS-CoV-2. The aim of this study was to evaluate the performance of the recently introduced MassARRAY<jats:sup>®</jats:sup> SARS-CoV-2 Panel and to compare it to the cobas<jats:sup>®</jats:sup> SARS-CoV-2 Test. </jats:sec> <jats:sec id="j_cclm-2021-0483_abs_002_w2aab3b7ab1b6b1aab1c11b2Aa"> <jats:title>Methods</jats:title> The MassARRAY<jats:sup>®</jats:sup> SARS-CoV-2 Panel consists of five assays targeting different sequences of the SARS-CoV-2 genome. Accuracy was determined using national and international proficiency panels including 27 samples. For clinical evaluation, 101 residual clinical samples were analyzed and results compared. Samples had been tested for SARS-CoV-2 RNA with the cobas<jats:sup>®</jats:sup> SARS-CoV-2 Test. </jats:sec> <jats:sec id="j_cclm-2021-0483_abs_003_w2aab3b7ab1b6b1aab1c11b3Aa"> <jats:title>Results</jats:title> When accuracy was tested with the MassARRAY<jats:sup>®</jats:sup> SARS-CoV-2 Panel, 25 of 27 (92.6%) samples revealed correct results. When clinical samples were analyzed with the MassARRAY<jats:sup>®</jats:sup> SARS-CoV-2 Panel and compared to the cobas<jats:sup>®</jats:sup> SARS-CoV-2 Test, 100 samples showed concordant results. One sample was found to be inconclusive with the MassARRAY<jats:sup>®</jats:sup> SARS-CoV-2 Panel. When time-to-results were compared, the new assay showed longer total and hands-on times. </jats:sec> <jats:sec id="j_cclm-2021-0483_abs_004_w2aab3b7ab1b6b1aab1c11b4Aa"> <jats:title>Conclusions</jats:title> The MassARRAY<jats:sup>®</jats:sup> SARS-CoV-2 Panel showed a good performance and proved to be suitable for use in the routine diagnostic laboratory. Especially during phases of shortage of reagents and/or disposables, the new test system appears as beneficial alternative to standard assays used for detection of SARS-CoV-2 RNA. </jats:sec>
In application/xml+jats format

Archived Files and Locations

application/pdf  530.8 kB
file_vqv5fe6hurdxxgsv5zkga63tea
web.archive.org (webarchive)
www.degruyter.com (publisher)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Date   2021-08-12
Language   en ?
Container Metadata
Not in DOAJ
In Keepers Registery
ISSN-L:  1434-6621
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: d808f360-58fc-4618-8420-4e8e7255b2a9
API URL: JSON